McKesson Reports Strong Q3 Earnings, Raises EPS Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2026
0mins
Should l Buy MCK?
Source: Benzinga
McKesson Corp's stock surged by 9.49% as it reached a 52-week high, reflecting strong investor confidence following its impressive Q3 earnings report.
The company reported Q3 revenues of $106.2 billion, an 11% year-over-year increase, and raised its fiscal 2026 earnings per share guidance to a range of $38.80 to $39.20. This reflects a 17% to 19% year-over-year growth, showcasing management's confidence in future performance. Additionally, McKesson's non-GAAP EPS reached $9.34, exceeding market expectations, driven by robust performance in the North American Pharmaceutical segment, particularly in oncology and multispecialty services.
These results indicate a solid market position for McKesson, bolstered by successful acquisition integrations and technology-driven efficiency gains. The raised guidance further enhances investor sentiment, suggesting a positive outlook for the company in the upcoming quarters.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MCK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MCK
Wall Street analysts forecast MCK stock price to fall
14 Analyst Rating
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 987.370
Low
880.00
Averages
942.83
High
1000.00
Current: 987.370
Low
880.00
Averages
942.83
High
1000.00
About MCK
McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Market Recap: Oil Prices Surge, CrowdStrike Upgraded
- Market Volatility: The S&P 500 fell on Monday but briefly rebounded after the U.S. and Israel launched an attack on Iran, causing oil prices to spike; WTI crude prices, while off their highs, indicate a defensive market stance.
- CrowdStrike Upgrade: Piper Sandler upgraded CrowdStrike from hold to buy with a $520 price target, arguing that the nearly 19% year-to-date pullback is excessive, and sees AI as an opportunity rather than a threat, boosting market confidence.
- Nvidia Strategic Investments: Nvidia shares rose over 3% after being named a top pick by Morgan Stanley, with analysts noting that despite stagnant stock performance in the last two quarters, business has strengthened; the company announced $2 billion investments in both Coherent and Lumentum, highlighting its strategic focus in optics technology.
- Investor Recommendations: Jim Cramer advised investors without Nvidia positions to buy the stock, asserting that its current depressed price won't last long, even as Monday's gains still left shares lower year-to-date.
See More
Jim Cramer's Investment Advice Amid Middle East Tensions
- Selective Investment Strategy: Jim Cramer advises investors to be selective following the U.S.-Israeli conflict with Iran, noting that while stocks initially sold off, there is no need for a full portfolio overhaul, particularly as the long-term narrative around artificial intelligence remains intact.
- Healthcare Sector Opportunities: Cramer recommends investing in the healthcare sector, asserting it will remain insulated from economic fallout, and initiated a position in Cardinal Health on Monday morning, which plays a crucial role in healthcare distribution and is pursuing growth through acquisitions.
- Reducing Oil Exposure: Cramer highlights that the market reaction creates opportunities to lighten oil positions, suggesting a 50% reduction in holdings due to inflated valuations from rising oil prices, drawing on historical patterns where such stocks tend to decline after initial spikes.
- Cautious on Consumer Staples: While Procter & Gamble is typically viewed as a classic defensive stock, Cramer expresses caution, indicating that rising oil prices could squeeze consumer spending, potentially impacting the performance of such stocks.
See More
Investment Analysis of Cardinal Health
- New Investment Move: Shortly after the opening bell, Jim Cramer's Charitable Trust will purchase 170 shares of Cardinal Health at approximately $229, resulting in a 1% ownership stake, reflecting confidence in the company's prospects.
- Market Reaction: Stocks are expected to open sharply lower on Monday due to weekend strikes in Iran, with crude oil prices climbing above $70, heightening concerns about geopolitical risks and inflation, which complicates the market landscape.
- Long-Term Growth Potential: Cardinal Health plays a crucial role in the U.S. healthcare sector, generating 99% of its revenue domestically, and the ongoing increase in the aging population in the U.S. is expected to provide significant long-term growth tailwinds over the next three decades.
- Profitability Enhancement: Despite market volatility, Cardinal Health's stock has risen over 70% in the past 12 months and approximately 10% year-to-date, trading at a price-to-earnings ratio of 21 times, indicating strong potential for sustained double-digit earnings growth.
See More
Cardinal Health Added to Watchlist
- Strong Industry Position: Cardinal Health serves as a backbone of the U.S. healthcare industry, supplying and distributing medicines and medical products to hospitals, retail pharmacies, and clinics, thereby ensuring its core role in the healthcare supply chain.
- Demographic Tailwind: With the continuous increase in the U.S. population aged 65 and over, Cardinal Health is expected to benefit from this long-term trend, as over 50% of this age group takes four or more medications, driving business growth.
- Market Reaction: Although shares sold off sharply on February 12 due to a logistics company announcing a new tool, the market quickly recognized the overreaction, and the stock rebounded swiftly, demonstrating its economic resilience.
- Attractive Valuation: Despite Cardinal Health's stock gaining about 10% over the past 12 months, it trades at just 21 times 2026 earnings estimates, which remains attractive relative to its historical levels, reflecting its potential for sustained double-digit earnings per share growth.
See More
FDA Pushes for Prescription Drugs to Become Over-the-Counter
- Policy Advocacy: FDA Commissioner Marty Makary stated in Washington that the agency plans to push for more prescription drugs to become over-the-counter (OTC) this year, aiming to improve drug accessibility and reduce healthcare costs, which could allow patients to obtain basic safe medications without a doctor's visit.
- Regulatory Streamlining: Legislation passed by Congress in November simplifies the regulatory process for transitioning prescription drugs to OTC status, including full, conditional, and partial switch pathways, which is expected to accelerate drug availability and enhance patient convenience in medication access.
- Increased Transparency: Makary emphasized that OTC sales would bypass insurers and pharmacy benefit managers, potentially lowering drug prices and increasing transparency, with cash prices for OTC medications possibly being lower than patients' copays for prescription drugs, thereby alleviating financial burdens on patients.
- Industry Pushback: The pharmaceutical industry has raised concerns about this policy, arguing that OTC drugs may not be covered by insurance, leading to higher costs for patients, and that the FDA lacks authority over drug pricing, necessitating thorough consultations with manufacturers before any transitions.
See More
Meta Deepens Partnership with Nvidia; Market Dynamics Analysis
- Meta and Nvidia Partnership: Meta commits to purchasing millions of Nvidia chips for its AI data centers, reflecting ongoing demand for AI hardware as Nvidia shares rise nearly 2% while Meta remains flat, indicating intensified competition in the sector.
- Palo Alto Networks Earnings: Despite reporting a quarterly beat, Palo Alto Networks shares fell over 6% after the company lowered its full-year earnings guidance, highlighting market concerns regarding profitability and a reassessment of the cybersecurity sector.
- Cadence Design Systems Surge: Shares of Cadence Design Systems jumped 7% following better-than-expected results and guidance, enhancing its position in the semiconductor design software market and positively impacting its partner Nvidia.
- Western Digital Debt Reduction Plan: Western Digital plans to sell over $3 billion of its Sandisk stake to reduce debt; although Sandisk shares are on a three-day decline, they have gained over 140% year-to-date, reflecting strong demand in the memory storage market.
See More
Market Recap: Oil Prices Surge, CrowdStrike Upgraded
- Market Volatility: The S&P 500 fell on Monday but briefly rebounded after the U.S. and Israel launched an attack on Iran, causing oil prices to spike; WTI crude prices, while off their highs, indicate a defensive market stance.
- CrowdStrike Upgrade: Piper Sandler upgraded CrowdStrike from hold to buy with a $520 price target, arguing that the nearly 19% year-to-date pullback is excessive, and sees AI as an opportunity rather than a threat, boosting market confidence.
- Nvidia Strategic Investments: Nvidia shares rose over 3% after being named a top pick by Morgan Stanley, with analysts noting that despite stagnant stock performance in the last two quarters, business has strengthened; the company announced $2 billion investments in both Coherent and Lumentum, highlighting its strategic focus in optics technology.
- Investor Recommendations: Jim Cramer advised investors without Nvidia positions to buy the stock, asserting that its current depressed price won't last long, even as Monday's gains still left shares lower year-to-date.
See More
Jim Cramer's Investment Advice Amid Middle East Tensions
- Selective Investment Strategy: Jim Cramer advises investors to be selective following the U.S.-Israeli conflict with Iran, noting that while stocks initially sold off, there is no need for a full portfolio overhaul, particularly as the long-term narrative around artificial intelligence remains intact.
- Healthcare Sector Opportunities: Cramer recommends investing in the healthcare sector, asserting it will remain insulated from economic fallout, and initiated a position in Cardinal Health on Monday morning, which plays a crucial role in healthcare distribution and is pursuing growth through acquisitions.
- Reducing Oil Exposure: Cramer highlights that the market reaction creates opportunities to lighten oil positions, suggesting a 50% reduction in holdings due to inflated valuations from rising oil prices, drawing on historical patterns where such stocks tend to decline after initial spikes.
- Cautious on Consumer Staples: While Procter & Gamble is typically viewed as a classic defensive stock, Cramer expresses caution, indicating that rising oil prices could squeeze consumer spending, potentially impacting the performance of such stocks.
See More
Investment Analysis of Cardinal Health
- New Investment Move: Shortly after the opening bell, Jim Cramer's Charitable Trust will purchase 170 shares of Cardinal Health at approximately $229, resulting in a 1% ownership stake, reflecting confidence in the company's prospects.
- Market Reaction: Stocks are expected to open sharply lower on Monday due to weekend strikes in Iran, with crude oil prices climbing above $70, heightening concerns about geopolitical risks and inflation, which complicates the market landscape.
- Long-Term Growth Potential: Cardinal Health plays a crucial role in the U.S. healthcare sector, generating 99% of its revenue domestically, and the ongoing increase in the aging population in the U.S. is expected to provide significant long-term growth tailwinds over the next three decades.
- Profitability Enhancement: Despite market volatility, Cardinal Health's stock has risen over 70% in the past 12 months and approximately 10% year-to-date, trading at a price-to-earnings ratio of 21 times, indicating strong potential for sustained double-digit earnings growth.
See More
Cardinal Health Added to Watchlist
- Strong Industry Position: Cardinal Health serves as a backbone of the U.S. healthcare industry, supplying and distributing medicines and medical products to hospitals, retail pharmacies, and clinics, thereby ensuring its core role in the healthcare supply chain.
- Demographic Tailwind: With the continuous increase in the U.S. population aged 65 and over, Cardinal Health is expected to benefit from this long-term trend, as over 50% of this age group takes four or more medications, driving business growth.
- Market Reaction: Although shares sold off sharply on February 12 due to a logistics company announcing a new tool, the market quickly recognized the overreaction, and the stock rebounded swiftly, demonstrating its economic resilience.
- Attractive Valuation: Despite Cardinal Health's stock gaining about 10% over the past 12 months, it trades at just 21 times 2026 earnings estimates, which remains attractive relative to its historical levels, reflecting its potential for sustained double-digit earnings per share growth.
See More
FDA Pushes for Prescription Drugs to Become Over-the-Counter
- Policy Advocacy: FDA Commissioner Marty Makary stated in Washington that the agency plans to push for more prescription drugs to become over-the-counter (OTC) this year, aiming to improve drug accessibility and reduce healthcare costs, which could allow patients to obtain basic safe medications without a doctor's visit.
- Regulatory Streamlining: Legislation passed by Congress in November simplifies the regulatory process for transitioning prescription drugs to OTC status, including full, conditional, and partial switch pathways, which is expected to accelerate drug availability and enhance patient convenience in medication access.
- Increased Transparency: Makary emphasized that OTC sales would bypass insurers and pharmacy benefit managers, potentially lowering drug prices and increasing transparency, with cash prices for OTC medications possibly being lower than patients' copays for prescription drugs, thereby alleviating financial burdens on patients.
- Industry Pushback: The pharmaceutical industry has raised concerns about this policy, arguing that OTC drugs may not be covered by insurance, leading to higher costs for patients, and that the FDA lacks authority over drug pricing, necessitating thorough consultations with manufacturers before any transitions.
See More
Meta Deepens Partnership with Nvidia; Market Dynamics Analysis
- Meta and Nvidia Partnership: Meta commits to purchasing millions of Nvidia chips for its AI data centers, reflecting ongoing demand for AI hardware as Nvidia shares rise nearly 2% while Meta remains flat, indicating intensified competition in the sector.
- Palo Alto Networks Earnings: Despite reporting a quarterly beat, Palo Alto Networks shares fell over 6% after the company lowered its full-year earnings guidance, highlighting market concerns regarding profitability and a reassessment of the cybersecurity sector.
- Cadence Design Systems Surge: Shares of Cadence Design Systems jumped 7% following better-than-expected results and guidance, enhancing its position in the semiconductor design software market and positively impacting its partner Nvidia.
- Western Digital Debt Reduction Plan: Western Digital plans to sell over $3 billion of its Sandisk stake to reduce debt; although Sandisk shares are on a three-day decline, they have gained over 140% year-to-date, reflecting strong demand in the memory storage market.
See More
